Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Cardiol Therapeutics Inc.NASDAQ: CRDL

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of CA$26.78K rose 7.2% year over year, ahead of the -69.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 3.1% from the prior quarter. Over 3 fiscal years it compounded at -22.6% a year.

Context

  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +7.2% holds above the trailing-twelve-month pace of -69.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$26.78K+3.1% QoQ
Last fiscal yearDec 2025
CA$101.98K-72.7% YoY
LTMMar 2026
CA$103.77K-69.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.2%——
1 year-72.7%——
3-year CAGR-22.6%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

CAD · from the cash flow

Latest · FY2025
101.98K CAD
Year-over-year change
-72.7%
4-year CAGR
-17.5%

Depreciation & Amortization vs competitors

How CRDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -69.2% is the lowest of 9, against a peer median of +9.4%.
  • Over three fiscal years its annual growth of -22.6% compares with a peer median of -7.5%.
CRDL Competitors
Depreciation & Amortization for CRDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASRTAssertio Holdings, Inc.LTM Mar 2026$26.58M USD-9.6%-3.5%26.0%
INCRInterCure Ltd.LTM Jun 2025₪8.45M ILS+33.4%+13.6%3.5%
HYPRHyperfine, Inc.LTM Mar 2026$1.38M USD+41.1%+2.4%9.0%
CNTBConnect Biopharma Holdings LimitedFY2025$704K USD+6.7%-11.4%1100.0%
IMAImageneBio IncLTM Mar 2026$616K USD+72.1%-24.1%—
VANIVivani Medical, Inc.LTM Mar 2026$452K USD+12.2%+3.6%—
IFRXInflaRx N.V.LTM Mar 2026€377.74K EUR-20.5%-12.3%1287.9%
CRDLCardiol Therapeutics Inc.LTM Mar 2026CA$103.77K CAD-69.2%-22.6%—
MBOTMicrobot Medical Inc.LTM Mar 2026$44K USD-43.6%-22.8%41.9%
KLRSKalaris Therapeutics IncLTM Mar 2026$20K USD———
Peer median (excluding CRDL) —+9.4%-7.5%34.0%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(31.64M)(30.93M)(28.13M)(36.68M)(33.82M)
Depreciation & Amortization220.42K219.91K248.36K373.11K101.98K
Deferred Income Tax(4.92M)(9.16M)000
Stock-Based Compensation8.5M5.01M4.16M14.28M10.7M
Change in Working Capital76.52K5.75M(545.88K)(931.57K)(733.34K)
Accounts Receivables(59.95K)(144.18K)200.33K(81.75K)135.43K
Inventory17.97K(4.47M)000
Accounts Payables2.39M4.47M000
Other Working Capital(2.27M)5.89M(746.2K)(849.82K)(868.76K)
Other Non-Cash Items4.21M1.89M(911.39K)(2.1M)(105.34K)
Operating Cash Flow(23.55M)(27.22M)(25.18M)(25.06M)(23.85M)
Capital Expenditures(12.92K)(74.71K)(64.31K)(21.29K)(24.48K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(12.92K)(74.71K)(64.31K)(21.29K)(24.48K)
Debt Repayment(51.92K)(53.93K)(55.38K)(41.53K)(55.38K)
Common Stock Issued84.08M0021.36M16.07M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.41M(0)0(2.47M)(477.03K)
Financing Cash Flow93.44M(53.93K)(55.38K)18.84M15.54M
Effect of Forex Changes(11.13K)2.92M762.04K1.89M(824.04K)
Net Change in Cash69.87M(24.43M)(24.54M)(4.35M)(9.16M)
Free Cash Flow(23.56M)(27.3M)(25.24M)(25.08M)(23.88M)

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.